New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Summary.
Bischof Delaloye
Angelika
A
Department of Nuclear Medicine, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland. Angelika.BischofDelaloye@chuv.ch
Conti
Peter S
PS
Gisselbrecht
Christian
C
Gregory
Stephanie A
SA
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000532:radiotherapy*; D016499:Radioimmunotherapy / Q000379:methods*; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan